HCM 6-K: Regulatory action

HUTCHMED

Filed with the SEC on · accession 0001648257-26-000078

HCM filed a 6-K (foreign company report) with the SEC on Nov 16, 2026. How foreign companies listed in the US report news and events — like an 8-K for them.

Summary of the filing

HUTCHMED announced that its drugs ELUNATE and ORPATHYS received expanded coverage on China's National Reimbursement Drug List (NRDL).

Key details

RegistrantHUTCHMED (China) Limited
Chief financial officerJohnny Cheng

✦ Ask GOAX AI about this filing — what it means for HCM, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for HCM?

Click here

Frequently asked questions

What did HCM file with the SEC on Nov 16, 2026?

HCM filed a 6-K (Regulatory action). HUTCHMED announced that its drugs ELUNATE and ORPATHYS received expanded coverage on China's National Reimbursement Drug List (NRDL).

What does a regulatory action mean for HCM stock?

A settlement removes uncertainty; the stock often reacts to whether the amount is bigger or smaller than investors expected.

How do I read a 6-K?

How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.

Other HCM SEC filings

Get alerts when HCM files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days